About
Cellect Biotechnology develops solutions for immune system regeneration. Its platform technology is based on the idea that the functional properties of stem cells, rather than their appearance, should be used for their identification, selection, and utilization. The companys first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents. These molecules induce apoptosis in mature cells while sparing stem cells, and this differential sensitivity is used to dramatically improve the outcome of bone marrow transplants. By achieving selectivity, specificity, and decreased toxicity, Cellect Biotechnology envisions its products becoming an integral and essential part of bone marrow transplants and being integrated into many aspects of regenerative medicine. In January 2018, Cellect Biotechnology signed an agreement with Hadassah Medical Center to conduct a clinical trial of the companys ApoGraft. In April 2018, the company announced it had completed POC testing for the first scalable production of ApoTainer, which is designed to replace the highly complex and expensive procedures currently used by laboratories (e.g. bone marrow transplants), providing a significantly more effective process at a fraction of the time and cost.
Funding history · 1 round · $24.3M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current status of Cellect Biotechnology?
- Cellect Biotechnology is currently inactive, having been acquired by Quoin Pharmaceuticals in November 2021.
- When was Cellect Biotechnology founded and where is it headquartered?
- Cellect Biotechnology was founded in June 2011 and is headquartered in Kefar Sava, Israel.
- What was Cellect Biotechnology's total funding raised?
- Cellect Biotechnology raised a total of $24,257,523 USD. For a full financing history, please refer to startupim.
- When did Cellect Biotechnology conduct a clinical trial for its ApoGraft product?
- In January 2018, Cellect Biotechnology signed an agreement with Hadassah Medical Center to conduct a clinical trial for its ApoGraft product.
- What significant milestone did Cellect Biotechnology achieve in April 2018 regarding ApoTainer?
- In April 2018, Cellect Biotechnology announced the completion of POC testing for the first scalable production of ApoTainer, a product designed to simplify and reduce the cost of stem cell procedures like bone marrow transplants.
- When did Cellect Biotechnology initiate a U.S. clinical trial for ApoGraft?
- Cellect Biotechnology initiated a U.S. clinical trial of ApoGraft in October 2020.
- What patent was granted to Cellect Biotechnology by the European Patent Office in August 2020?
- In August 2020, the European Patent Office granted Cellect Biotechnology a pivotal patent for stem cells activation.
- What was the outcome of the collaboration between Cellect Biotechnology and Cell2in in March 2019?
- In March 2019, Cellect Biotechnology announced positive results from its collaboration with Cell2in, showing significant improvement in the expansion rate and function of stem cells.
- When did Cellect Biotechnology begin a collaboration with Washington University for a U.S. clinical trial?
- In February 2019, Cellect Biotechnology began a collaboration with Washington University in preparation for its first U.S. clinical trial using ApoGraft for bone marrow transplantations.